Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sotyktu
Biotech
J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials.
James Waldron
Mar 10, 2025 7:30am
BMS backs out of Dupixent fight, axing asset despite phase 3 win
Feb 7, 2025 6:26am
Alumis plans IPO to fund TYK2 inhibitor through phase 3 trials
Jun 10, 2024 8:35am
How Takeda beat the rest of the industry to snag Nimbus' TYK2
Jan 11, 2024 10:30am
Nimbus tacks on $210M as investors swat away IRA concerns
Sep 6, 2023 7:00am
Takeda's $4B drug clears psoriasis in one-third of patients
Mar 20, 2023 8:15am
